Johnson & Johnson MedTech Acquires Laminar, Inc.
November 30, 2023
Johnson & Johnson MedTech has completed the acquisition of Laminar, Inc., a privately held medical device developer focused on eliminating the left atrial appendage (LAA) in patients with non‑valvular atrial fibrillation, for $400 million upfront plus potential clinical and regulatory milestone payments. Laminar will join Johnson & Johnson MedTech’s Biosense Webster business to expand the company’s electrophysiology and interventional cardiology portfolio and accelerate development and commercialization of Laminar’s rotational LAA elimination technology.
- Buyers
- Johnson & Johnson MedTech, Biosense Webster, Inc.
- Targets
- Laminar, Inc.
- Industry
- Medical Devices
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Johnson & Johnson Completes Acquisition of V‑Wave Ltd.
October 9, 2024
Medical Devices
Johnson & Johnson has completed its acquisition of V‑Wave Ltd., adding V‑Wave’s Ventura Interatrial Shunt to the Johnson & Johnson MedTech portfolio. The transaction was accounted for as an asset acquisition and will result in an in‑process R&D charge of approximately $600 million as J&J expands its cardiovascular and heart‑failure capabilities.
-
Laborie Acquires the JADA® System from Organon
January 28, 2026
Medical Devices
Laborie Medical Technologies has completed the acquisition of the JADA® System and the team behind it from Organon in a transaction announced in late January 2026. The deal — part of Organon’s divestiture program (previously disclosed as up to $465 million) — brings more than 90 employees and an FDA-cleared device for rapid control of postpartum hemorrhage into Laborie’s obstetrics portfolio to expand the company’s maternal health capabilities.
-
Johnson & Johnson Acquires Abiomed
December 22, 2022
Medical Devices
Johnson & Johnson completed its acquisition of Abiomed on December 22, 2022, acquiring all outstanding shares for $380.00 per share (approximately $16.6 billion enterprise value) plus a contingent value right. Abiomed will operate as a standalone business within Johnson & Johnson's MedTech segment, expanding J&J's capabilities in high-growth cardiovascular and heart-recovery solutions.
-
Aileron Therapeutics Acquires Lung Therapeutics
October 31, 2023
Biotechnology
Aileron Therapeutics, Inc. (NASDAQ: ALRN) completed a stock-for-stock acquisition of Lung Therapeutics, Inc., bringing the clinical-stage pulmonary and fibrosis-focused pipeline (including lead candidate LTI-03) into Aileron's portfolio. Immediately after the acquisition Aileron arranged a private placement led by Bios Partners (with participation from Nantahala Capital and others) to raise approximately $18 million to fund ongoing development, including a Phase 1b trial of LTI-03.
-
Marketlab Acquires Assets of Medi‑Tech International Corporation
September 12, 2023
Medical Devices
Marketlab, a family-owned manufacturer of specialty healthcare products based in Caledonia, Michigan, has acquired the assets of Medi‑Tech International Corporation, a Brooklyn, New York‑based manufacturer of wound care, labor‑and‑delivery, and patient safety products. The acquisition expands Marketlab’s medical‑surgical and laboratory product portfolio and brings additional products, distribution partnerships, and GPO contracts into its offering to better serve IDNs and other healthcare customers.
-
Boston Scientific Acquires Lumenis Surgical Business from Baring Private Equity Asia for $1.07B
March 3, 2021
Medical Devices
Boston Scientific has agreed to acquire the Lumenis Surgical Business from Baring Private Equity Asia/Lumenis for USD 1.07 billion, subject to closing adjustments. The deal transfers Lumenis' surgical laser portfolio and global surgical team (including its Israeli laser center of excellence) to Boston Scientific to bolster its Urology strategy, while Lumenis — still owned by BPEA — will focus on Aesthetics and Vision.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.